MedTrace Logo

Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes

NCT01707134 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 753

Last updated 2017-01-04

No results posted yet for this study

Summary

This trial is conducted in Europe. The aim of this trial is to evaluate the safety profile of insulin aspart in subjects with type 1 diabetes having participated in trial ANA/DCD/035.

Conditions

Interventions

DRUG

insulin aspart

Injected subcutaneously (s.c, under the skin) as meal time insulin

DRUG

human soluble insulin

Injected subcutaneously (s.c, under the skin) as meal time insulin

DRUG

insulin NPH

Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR,1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-09-30
Primary Completion
2000-05-31
Completion
2000-05-31

Countries

  • Austria
  • Denmark
  • Finland
  • Germany
  • Norway
  • Sweden
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01707134 on ClinicalTrials.gov